All Blogs / Industries / Medical / Pharmaceutical / New
Would you take a sleeping pill that gives you suicidal thoughts?
The FDA says an experimental Merck drug, suvorexant, helps patients fall asleep but has worrisome side effects, including suicidal thinking. The FDA said company trials showed the pill consistently worked better than a placebo. But patients taking higher doses had an eight-fold increase in daytime drowsiness that interfered with driving. Show More Summary
Before consenting to any clinical trial ask: " can you guarantee the results will be published?"
http://www.pharmatimes.com/Article/13-05-21/NIHR_says_“it_s_OK_to_ask”_about_clinical_research.aspx?
In my humble opinion
This blog is a "must read", http://1boringoldman.com/
Breaking Up is Hard to Do: Lessons Learned from a Pharma-Free Practice Transformation
http://www.jabfm.org/content/26/3/332.full.pdf PORTLAND, Ore. – A new report suggests that improved health care and significant reductions in drug costs might be attained by breaking up the age-old relationship between physicians and drug company representatives who promote the newest, more costly and often unnecessary prescription drugs. Show More Summary
But Don't Drug Companies Spend More on Marketing?
So drug companies may spend a lot on R&D, but they spend even more on marketing, right? I see the comments are already coming in to that effect on this morning's post on R&D expenditures as a percentage of revenues. Let's take a look at those other numbers, then. We're talking SG&A, "sales, general, and administrative". Show More Summary
Actavis to Buy Warner Chilcott in $8.5 Billion Stock Deal
Published: Monday, 20 May 2013 | 8:11 AM ET By: Reuters With CNBC.com Generic drugmaker Actavis, which has been the subject of intense takeover speculation, said on Monday that it had struck a deal to buy specialty pharmaceuticals company Warner Chilcott for $8.5 billion in stock. Show More Summary
Ketamine Associated With Rapid Antidepressant Effect In Largest Clinical Trial To Date
Also Included In: Pain / Anesthetics Article Date: 20 May 2013 - 1:00 PDT Current ratings for: Ketamine Associated With Rapid Antidepressant Effect In Largest Clinical Trial To Date Patient / Public: Healthcare Prof: Patients with treatment-resistant...Show More Summary
How Much Do Drug Companies Spend on R&D, Anyway?
How much does Big Pharma spend on R&D, compared to what it takes in? This topic came up during a discussion here last week, when a recent article at The Atlantic referred to these expenditures as "only" 16 cents on the dollar, and IShow More Summary
Thalidomide - The Real Story & The First Seal Bab By James Linder Jones, M.D., M.H.A., FACEP
http://www.healthworldnet.com/articles/the-best-of-the-best/the-first-seal-baby-the-real-story-of-thalidomide.html Thalidomide, despite its sordid past is undergoing a sort of renaissance and is being manufactured and used worldwideShow More Summary
Why French Kids Don't Have ADHD
In the United States, at least 9% of school-aged children have been diagnosed with ADHD, and are taking pharmaceutical medications. In France, the percentage of kids diagnosed and medicated for ADHD is less than.5%. How come the epidemic...Show More Summary
Wealth but not health in the USA
The Lancet Last week, American people, health-care workers, and policy makers received shocking news. Despite spending more on health care per person than other high-income countries, Americans die sooner, are least likely to reach the age of 50 years, and have higher rates of disease or injury. Show More Summary
Royal College of Physicians support AllTrials
Royal College of Physicians statement The Council of the Royal College of Physicians (RCP) has agreed to support the principles of the ‘All trials registered, all trials reported’ campaign. This reflects the RCP’s commitment towards delivering greater transparency for the benefit of patient care. Show More Summary
Sweden's drug testing industry plummets
Sweden's once flourishing pharmaceutical testing industry has been decimated in recent years, suffering an 85-percent drop according to new figures that industry experts describe as "deeply troubling". AstraZeneca hit by steep drop in...Show More Summary
Measure Differently for Healthier Returns
This week my friend Shwen Gwee, Chief Digital Officer at Chandler Chicco, volunteered me to lead the ROI "Group Roundtable Discussions" at the Social Media for Pharma Conference in Princeton, NJ. This conference was organized by Advanced...Show More Summary
Weekly Roundup 5-17-13
It has been a busy May. From working in the yard to transform it from looking like property on which Boo Radley might have a house to putting on panel discussions and layers of business travel to grading papers and … Continue readi...
A Little Ranbaxy Example
Compare and contrast. Here we have Krishnan Ramalingam, from Ranbaxy's Corporate Communications department, in 2006: Being a global pharmaceutical major, Ranbaxy took a deliberate decision to pool its resources to fight neglected disease...Show More Summary
Will Narrowing Pharmacy Networks Squeeze Manufacturers?
Pharmaceutical Executive's May 2013 issue includes Pharmacy Benefit Networks: The Big Squeeze, a new article by yours truly.
The article's first half, excerpted from Chapter 8 of the 2012-13 Economic Report on Retail, Mail, and Specialty...Show More Summary
Oz Court rejects Merck deal over Vioxx
A Federal Court judge has refused drug company Merck's $540,000 settlement with Australians who claim its drug Vioxx caused them a heart attack, labelling the deal an "obvious injustice". More than 1700 people joined a class action against...Show More Summary
New Resources to Find Affordable Medications
As patients and consumers, we face more and more choices about our health care each year. We all support consumer empowerment in decisions about their care, but consumers don’t always have all the information they need to choose between different prescription drugs. And the billions of dollars that the drug industry spends on advertising to [...]
Ranbaxy: Looking Under the Rock
Here's an excellent, detailed look from Fortune at how things went off the rails at Ranbaxy and their generic atorvastatin (Lipitor). The company has been hit by a huge fine, and no wonder. This will give you the idea: On May 13, Ranbaxy...Show More Summary
- Supreme Court
- Affordable Care Act
- Prescription Drug
- European Medicines Agency
- Big Pharma
- New England Compounding Center
- Boehringer Ingelheim
- Eli Lilly
- School of Medicine
- Express Scripts
- British Pharmaceutical Industry
- Bristol-Myers Squibb
- Clinical Trial
- Novo Nordisk
- Bayer Healthcare
- Medicaid Services
- Philadelphia Inquirer
- Off-Label Promotion
- Marcia Angell
- John LaMattina
